Large gap with delayed quotes
|
Last quote
11/04/2025
-
17:07:49
|
Bid
11/04/2025 -
17:08:00
|
Bid Volume |
Ask
11/04/2025 -
17:08:00
|
Ask Volume |
|---|---|---|---|---|
|
16.71
-7.74
(
-31.66% )
|
16.69
|
100 |
16.72
|
700 |
Analysis date: 31.10.2025
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 28.10.2025.
Interest
Very strong
Very strong
Four stars since 28.10.2025.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 28.10.2025 at a price of 24.22.
Evaluation
Neutral
Neutral
Based on its growth potential and our own criteria, we believe the share price is currently fairly priced.
MT Tech Trend
Positive
Positive
The dividend-adjusted forty day technical trend is positive since 26.09.2025.
4wk Rel Perf
22.33%
22.33%
The four-week dividend-adjusted overperformance versus SP500 is 22.33%.
Sensibility
High
High
High, no change over 1 year.
Bear Market Factor
High
High
On average, the stock has a tendency to amplify the drops in the index by 1.04%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 7.76%.
Mkt Cap in $bn
2.35
2.35
With a market capitalization between $2 & $8bn, SAREPTA THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
1.11
1.11
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 0.9 indicates that the stock's price presents a discount to growth of
LT P/E
17.47
17.47
The estimated PE is for the year 2028.
LT Growth
19.31%
19.31%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
18
18
Over the last seven weeks, an average of 18 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
79
79
For 1% of index variation, the stock varies on average by 0.79%.
Correlation
0.18
0.18
Stock movements are totally independent of index variations.
Value at Risk
13.02
13.02
The value at risk is estimated at USD 13.02. The risk is therefore 54.23%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
21.05.2013
21.05.2013